Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

被引：1
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. A. [2 ]
Cheporov, S. V. [3 ]
Makhson, A. N. [4 ]
Manikhas, G. M. [5 ]
Clawson, A. [6 ]
Bhar, P. [6 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Leningrad Reg Oncol Ctr, Dept Chemotherapy, Kuzmolovo, Russia
[3] Yaroslavl Reg Clin Oncol Hosp, Dept Chemotherapy, Yaroslavl, Russia
[4] City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia
[5] St Petersburg City Oncol Ctr, Dept Chemotherapy, St Petersburg, Russia
[6] Celgene Corp, Biostat, Summit, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71502-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [31] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Wang, Chen
    Hao, Chunfang
    Wang, Xiaorui
    Meng, Wenjin
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer
    Seidman, A. D.
    Conlin, A. K.
    Bach, A.
    Forero-Torres, A.
    Wright, G.
    Hackney, M. H.
    Clawson, A.
    Schofield, D.
    Iglesias, J.
    Hudis, C. A.
    CANCER RESEARCH, 2011, 71
  • [33] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [34] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Docetaxel versus epirubicin/cyclophosphamide (EC) as first-line therapy in metastatic breast cancer (MBC): Results from the randomized phase II TIPP study.
    Wasemann, C
    Ertan, A
    Strunck, C
    Schmidt, W
    Diedrich, K
    Friedrich, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
  • [36] Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
    Hou, X. F.
    Li, S.
    Wu, C.
    Liu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S866 - S867
  • [37] A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Spigel, David R.
    Clark, Bobby L.
    Vazquez, Elizabeth
    Shipley, Dianna
    Barton, John
    Thompson, Dana
    Montes, Ignacio
    Greco, F. Anthony
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (04) : 247 - 252
  • [38] Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients: A randomized multicenter phase II trial
    Ghosn, M.
    Farhat, F. S.
    Kattan, J. G.
    Hanna, C.
    Younes, F.
    Haddad, N.
    Aftimos, P.
    Nasr, F.
    Moukadem, W.
    Chahine, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Results of first-line weekly paclitaxel (P) plus gemcitabine (G) in metastatic breast cancer (MBC): An AERO phase II trial
    Mousseau, M.
    Serin, D.
    Petit, T.
    Priou, F.
    Zelek, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
12345